Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Exelixis Inc EXEL
$58.16
โฒ +0.36%
(+$0.21)
Open
$58.25
Prev Close
$57.95
Day Range
$57.63 โ $58.62
52W Range
$33.76 โ $59.72
Market Cap
$14.41B
P/E (TTM)
16.75
Beta
0.48
EPS (TTM)
$3.18
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-04-11 |
| Shares Out. | 251,360,000 |
| Website | exelixis.com/ โ |
| Phone | 13026587581 |
| Employees | 1,077 |
| Revenue | $628.7M |
| Gross Profit | $608.0M |
| Net Income | $212.1M |
| Free Cash Flow | $1.17B |
| Total Assets | $2.49B |
| Total Liabilities | $650.5M |
| Equity | $1.84B |
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis Inc is a publicly traded company under the ticker symbol EXEL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
27 analysts (2026-09-01)
๐ฐ Latest News for EXEL
Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?
Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib แแแแแชแฎแแ tometastatic Colorectal Cancer
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
Exelixis: Why The 3-Month Delay Is More Negative Than It May Seemย (Downgrade)